SecBot SecBot
8-K ·Filed Apr 10, 2026

LYRA

Lyra Therapeutics, Inc.
BEARISH
Impact 7/10
Horizondays Processed6mo ago SEC0001193125-26-150441
8-K material event: Items 1.02
Actionable Insight ▼ Bearish

The termination of long-dated leases at significant cost suggests Lyra is undergoing a major restructuring or winding down operations. Traders should watch for further cost-cutting announcements, potential asset sales, or liquidity concerns given the substantial near-term cash outflow.

DirectionBearish
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
LYRA ▲ +9.13% at T+60d
SHORT call ✗ call lost -9.13% · α vs SPY +1.20% · entry $0.6500 → $0.7093
Entry = T+0 close
Apr 10, 2026
via day close
T+1d
0.00%
call 0.00% · α +0.98%
$0.6500
settled 7mo ago
T+5d
+23.78%
call -23.78% · α -19.28%
$0.8046
settled 6mo ago
T+20d
+15.38%
call -15.38% · α -6.86%
$0.7500
settled 6mo ago
T+60d
+9.13%
call -9.13% · α +1.20%
$0.7093
settled 4mo ago

Price Chart

Loading chart...

Executive Summary

Lyra Therapeutics terminated leases for its Watertown and Waltham facilities, incurring $3.9 million in total termination costs. This move signals a significant downsizing or restructuring effort, likely to reduce operating expenses amid financial pressure.

Key Facts

  • Terminated lease for 22,343 sq ft in Watertown, MA, originally set to expire April 30, 2027
  • Terminated lease for 28,858 sq ft in Waltham, MA, originally set to expire June 30, 2033
  • Total termination costs: $3.9 million, including $2.3 million in cash payments and $1.4 million in forfeited security deposits
  • Rent obligations already ceased as of January 31, 2026 (Watertown) and March 31, 2026 (Waltham)
  • Additional contingent payment of up to $1.5 million tied to a future sale transaction

Financial Impact

Approximately $3.9 million in immediate cash outflow and forfeited deposits, with up to $1.5 million more contingent on a sale transaction

cashoperating expenseslease liabilitiescontingent liabilities

Risk Factors

  • Substantial cash outflow could strain liquidity
  • Potential for future dilution or financing needs
  • Operational disruption from facility closures

Market Snapshot

Exchange
OTC
Sector
Surgical & Medical Instruments & Apparatus

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-150441
Document: 0001193125-26-150441-index-headers.html0001193125-26-150441
Document: 0001193125-26-150441-index.html0001193125-26-150441
Document: 0001193125-26-150441.txt0001193125-26-150441
4 reports for LYRA
Performance horizon
100% Hit rate @ T+60 3 of 3 directional calls Went positive at some point 3 of 3 best @ T+60▲ +47.53%Apr 17, 2026
Filters
Rows
Reports for LYRA — sortable, filterable
TypeNow
Apr 30, 2026
25w ago
15-12G
BEARISH ★ 7/10
$0.7050 $0.5200▲ +26.24%▲ +29.35%$0.1900 (+73.05%)
Apr 17, 2026
27w ago
8-K
BEARISH ★ 6/10
$0.8046 $0.4221▲ +47.53%▲ +53.68%$0.1900 (+76.39%)
Apr 17, 2026
27w ago
Press Release
BEARISH ★ 8/10
$0.8046 $0.4221▲ +47.53%▲ +53.68%$0.1900 (+76.39%)
Apr 10, 2026
28w ago
8-K
BEARISH ★ 7/10
$0.6500 $0.7093▼ −9.13%▲ +1.20%$0.1900 (+70.77%)
Showing 4 of 4

US Market Status

Market Closed — Opens Thu (11h 47m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 10, 2026